An international collaboration led by USC compiled the most comprehensive list of genetic variants associated with prostate cancer risk through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.
An international phase III clinical trial found that metastatic colorectal cancer patients with a rare genetic tumor mutation called KRAS G12C experienced superior progression-free survival rates compared to standard of care when offered a combination treatment of KRAS inhibitor sotorasib and monoclonal antibody panitumumab.
Part 1 of the phase III RUBY trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel) followed by dostarlimab as a single agent, compared to placebo plus chemotherapy followed by placebo in adult patients with primary advanced or recurrent endometrial cancer produced positive primary results from a planned analysis.
Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and experience higher rates of relapse and treatment toxicity. In recent decades, new therapies have improved outcomes for the general population, but outcomes for children with Down syndrome have lagged and have not been reported for contemporary treatment regimens.
Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found that the two test results differ because there are underlying subtle differences in the cells that make up an endometrial cancerous tumor.
A team of researchers from Japan and Singapore have found that integrating DNA methylation data with patients’ lifestyle and clinical data improves risk stratification for predicting gastric neoplasia (GN).
A retrospective study led by University of Cincinnati Cancer Center researchers showed that a device that acts as a GPS for surgeons to locate and remove breast and lymph node tumors was safe and effective.
The COVID-19 pandemic was associated with significant changes in diagnoses of all cancer types in 2020, with a 14.4% overall decline in the number of reported cancer cases in cancer centers accredited by the Commission on Cancer (CoC) compared with the prior year.
The phase III CheckMate -67T has met its co-primary pharmacokinetics endpoints and a key secondary endpoint of noninferior objective response rate.
The phase III MATTERHORN trial showed treatment with Imfinzi (durvalumab) in combination with standard-of-care FLOT neoadjuvant chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel given before surgery) demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of pathologic complete response versus neoadjuvant chemotherapy alone for patients with resectable, early-stage and locally advanced (stages 2, 3, 4A) gastric and gastroesophageal junction cancers.
